514 related articles for article (PubMed ID: 28624449)
1. Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb.
Uehara J; Ohkuri T; Kosaka A; Ishibashi K; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Ishida-Yamamoto A; Kobayashi H
Biochem Biophys Res Commun; 2017 Aug; 490(2):521-527. PubMed ID: 28624449
[TBL] [Abstract][Full Text] [Related]
2. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
[TBL] [Abstract][Full Text] [Related]
3. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
4. An Immunomodulatory Gallotanin-Rich Fraction From
Lasso P; Gomez-Cadena A; Urueña C; Donda A; Martinez-Usatorre A; Romero P; Barreto A; Fiorentino S
Front Immunol; 2020; 11():584959. PubMed ID: 33312174
[TBL] [Abstract][Full Text] [Related]
5. Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice.
Ueha S; Yokochi S; Ishiwata Y; Ogiwara H; Chand K; Nakajima T; Hachiga K; Shichino S; Terashima Y; Toda E; Shand FH; Kakimi K; Ito S; Matsushima K
Cancer Immunol Res; 2015 Jun; 3(6):631-40. PubMed ID: 25711759
[TBL] [Abstract][Full Text] [Related]
6. Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells.
Lai Q; Wang H; Li A; Xu Y; Tang L; Chen Q; Zhang C; Gao Y; Song J; Du Z
Oncogene; 2018 Apr; 37(17):2302-2312. PubMed ID: 29422611
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature.
Spaapen RM; Leung MY; Fuertes MB; Kline JP; Zhang L; Zheng Y; Fu YX; Luo X; Cohen KS; Gajewski TF
J Immunol; 2014 Oct; 193(8):4254-60. PubMed ID: 25217157
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral Plasmid IL12 Expands CD8
Telli ML; Nagata H; Wapnir I; Acharya CR; Zablotsky K; Fox BA; Bifulco CB; Jensen SM; Ballesteros-Merino C; Le MH; Pierce RH; Browning E; Hermiz R; Svenson L; Bannavong D; Jaffe K; Sell J; Foerter KM; Canton DA; Twitty CG; Osada T; Lyerly HK; Crosby EJ
Clin Cancer Res; 2021 May; 27(9):2481-2493. PubMed ID: 33593880
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
Simeone E; Ascierto PA
J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
[TBL] [Abstract][Full Text] [Related]
10. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
11. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
[TBL] [Abstract][Full Text] [Related]
12. Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth.
Kwak G; Kim D; Nam GH; Wang SY; Kim IS; Kim SH; Kwon IC; Yeo Y
ACS Nano; 2017 Oct; 11(10):10135-10146. PubMed ID: 28985469
[TBL] [Abstract][Full Text] [Related]
13. Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice.
Hu Z; Ye L; Xing Y; Hu J; Xi T
Sci Rep; 2018 Jan; 8(1):217. PubMed ID: 29317734
[TBL] [Abstract][Full Text] [Related]
14. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
Zhu X; Xu J; Cai H; Lang J
J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
[TBL] [Abstract][Full Text] [Related]
16. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A
Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.
Mauldin IS; Wages NA; Stowman AM; Wang E; Smolkin ME; Olson WC; Deacon DH; Smith KT; Galeassi NV; Chianese-Bullock KA; Dengel LT; Marincola FM; Petroni GR; Mullins DW; Slingluff CL
Cancer Immunol Immunother; 2016 Oct; 65(10):1189-99. PubMed ID: 27522581
[TBL] [Abstract][Full Text] [Related]
19. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]